Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOUNDTRACK-B study of surovatamig in relapsed or refractory B-cell non-Hodgkin lymphoma
2023-505789-27-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Apr 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 16
01
Overview
Phase 2, open-label, single-arm trial of surovatamig in mature B-cell lymphoma and non-Hodgkin lymphoma (NHL), sponsored by AstraZeneca. Primary endpoint: Overall response rate. Planned start Apr 2025; status: authorised.
02
Drugs
surovatamig
03
Conditions
mature B-cell lymphomanon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2023-505789-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505789-27-00.